arginyl-glycyl-aspartic acid has been researched along with Lung Adenocarcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, JW; Kim, J; Kim, SW; Nam, HY; Yun, CO | 1 |
| Dong, C; Feng, C; Gao, Y; Li, X; Zhang, X | 1 |
2 other study(ies) available for arginyl-glycyl-aspartic acid and Lung Adenocarcinoma
| Article | Year |
|---|---|
Efficient lung orthotopic tumor-growth suppression of oncolytic adenovirus complexed with RGD-targeted bioreducible polymer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adenoviridae; Cell Line, Tumor; Fibrosarcoma; HEK293 Cells; Humans; Liver; Lung Neoplasms; Oligopeptides; Oncolytic Virotherapy; Oncolytic Viruses; Polyethylene Glycols; Polymers; RNA Interference; RNA, Small Interfering | 2014 |
RGD-modified liposomes enhance efficiency of aclacinomycin A delivery: evaluation of their effect in lung cancer.
Topics: Aclarubicin; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antibiotics, Antineoplastic; Area Under Curve; Cell Line, Tumor; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Stability; Half-Life; Injections, Intravenous; Lipids; Liposomes; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Oligopeptides; Particle Size; Rats; Solubility; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |